A new experimental drug called KR-36996 reduced liver damage, inflammation, and scarring in mice with severe fatty liver disease, according to research published in 2026. The drug blocks a protein called the urotensin II receptor and decreased liver injury markers by reducing inflammatory cells and scar tissue formation. However, the drug has only been tested in mice and has not yet been evaluated in humans.
Researchers tested a new experimental drug called KR-36996 on mice with a severe form of fatty liver disease that causes inflammation and scarring. According to Gram Research analysis, the drug reduced liver damage, decreased inflammation, and slowed the scarring process. The drug works by blocking a specific protein involved in liver injury. While these results are encouraging, the study was done in mice, so scientists will need to test it in humans before it becomes available as a treatment. This research opens a new pathway for treating metabolic dysfunction-associated steatohepatitis, a condition affecting millions of people worldwide.
Key Statistics
A 2026 research study found that KR-36996, an orally active urotensin II receptor antagonist, reduced liver inflammation markers and decreased collagen deposition in mice with methionine- and choline-deficient diet-induced fatty liver disease.
The experimental drug reduced accumulation of inflammatory immune cells (F4/80-positive macrophages) and lowered expression of inflammation-promoting genes including IL-1 beta, CCL2, and TNF alpha in treated mice.
KR-36996 decreased fibrosis markers including alpha-smooth muscle actin immunoreactivity and reduced JNK phosphorylation, a key signaling pathway involved in liver scarring, in the mouse model of steatohepatitis.
The Quick Take
- What they studied: Whether a new drug called KR-36996 could reduce liver damage, inflammation, and scarring in mice with a severe form of fatty liver disease.
- Who participated: Male laboratory mice (C57BL/6 strain) that were fed a special diet designed to cause fatty liver disease with inflammation and scarring, similar to the human condition.
- Key finding: The drug significantly reduced liver damage markers, decreased inflammation in the liver, and slowed the development of scar tissue compared to untreated mice.
- What it means for you: This research suggests a potential new treatment approach for fatty liver disease, but it’s still in early stages. The drug was only tested in mice, so human trials would be needed before it could become a medical treatment. If successful in humans, it could help people with severe fatty liver disease avoid liver damage.
The Research Details
Scientists used laboratory mice to test whether KR-36996 could treat a severe form of fatty liver disease. They fed mice a special diet lacking certain nutrients (methionine and choline) that causes the liver to become fatty, inflamed, and scarred, mimicking the human disease. Half the mice received the experimental drug by mouth daily for four weeks, while the other half did not receive treatment. After four weeks, researchers examined the mice’s livers and blood to measure damage, inflammation, and scarring. They used multiple methods to assess the results, including blood tests, tissue examination under a microscope, and molecular analysis to measure specific proteins and genes involved in liver damage.
This research approach is important because it tests a new drug mechanism that hasn’t been explored before for this disease. By using a mouse model that closely resembles human fatty liver disease, researchers can determine whether blocking the urotensin II receptor (a specific protein) is a viable treatment strategy before investing in expensive human trials. The study measured multiple aspects of liver damage, providing a comprehensive picture of how the drug works.
This is a controlled laboratory study with clear treatment and control groups, which is a reliable way to test whether a drug works. However, results in mice don’t always translate to humans, so this is an early-stage finding. The study measured multiple markers of liver health, which strengthens the evidence. The research was published in a peer-reviewed scientific journal, meaning other experts reviewed it before publication.
What the Results Show
The drug KR-36996 significantly reduced liver damage in treated mice. Blood tests showed lower levels of liver enzymes (ALT and AST), which are markers of liver injury. When researchers examined liver tissue under a microscope, they found less inflammation in the livers of treated mice compared to untreated mice. Specifically, there were fewer inflammatory cells and less accumulation of immune cells called macrophages that contribute to liver damage. The drug also reduced the expression of genes that promote inflammation, including genes for IL-1 beta, CCL2, and TNF alpha. These findings indicate the drug successfully reduced the inflammatory response in the liver.
Beyond reducing inflammation, KR-36996 also slowed the development of liver scarring (fibrosis). Treated mice had less collagen deposited in their livers, which is the main component of scar tissue. The drug reduced markers of fibrosis, including lower levels of proteins involved in scar formation. Molecular analysis showed that the drug worked by blocking a specific signaling pathway called JNK phosphorylation, which is involved in tissue damage and scarring. Interestingly, the drug did not significantly reduce fat accumulation in the liver itself, suggesting it primarily works by reducing inflammation and scarring rather than preventing fat buildup.
This research is novel because it’s the first study examining the urotensin II receptor system in fatty liver disease. Previous research has shown this system is involved in other chronic liver conditions, but its role in metabolic dysfunction-associated steatohepatitis was unknown. The findings suggest that blocking this receptor could be a new therapeutic approach, complementing existing treatments that focus on other mechanisms of liver damage.
This study was conducted only in mice, so results may not directly apply to humans. The mice were all male, so the findings may not apply equally to females. The study used a specific diet-induced model of fatty liver disease, which may not perfectly replicate all aspects of the human condition. The drug was tested at only one dose level, so optimal dosing in humans is unknown. Additionally, the study lasted only four weeks, so long-term effects and safety are not yet established.
The Bottom Line
This research is too early-stage to make clinical recommendations. The drug has only been tested in mice and has not been evaluated in humans. Before KR-36996 could be used as a treatment, it would need to undergo extensive human clinical trials to confirm safety and effectiveness. People with fatty liver disease should continue following their doctor’s current recommendations, which typically include weight loss, dietary changes, and management of related conditions like diabetes.
This research is most relevant to people with metabolic dysfunction-associated steatohepatitis (MASH), a severe form of fatty liver disease with inflammation and scarring. It’s also important for researchers and pharmaceutical companies developing new liver disease treatments. People with milder forms of fatty liver disease may benefit in the future if this drug proves effective in human trials. Healthcare providers treating liver disease should monitor this research as it progresses.
This is very early-stage research. If the drug moves forward, it would typically take 5 to 10 years of additional research and clinical trials before it could potentially become available as a treatment. The next step would be testing in a small group of human volunteers to assess safety, followed by larger trials to confirm effectiveness.
Frequently Asked Questions
What is fatty liver disease and why is it dangerous?
Fatty liver disease occurs when fat accumulates in liver cells. In severe cases (MASH), it causes inflammation and scarring that can lead to liver failure. It’s often linked to obesity, diabetes, and metabolic problems.
How does KR-36996 treat fatty liver disease differently from existing treatments?
This drug blocks the urotensin II receptor, a protein involved in inflammation and scarring. Most current treatments focus on weight loss and managing related conditions. This drug targets a specific biological pathway not previously explored for this disease.
When will KR-36996 be available as a treatment for patients?
The drug is still in early research stages and has only been tested in mice. If development continues, it would typically take 5 to 10 years of additional testing and human clinical trials before potential approval for patient use.
Can I use this drug now if I have fatty liver disease?
No, KR-36996 is not available for patient use. It’s an experimental drug in research phase. People with fatty liver disease should work with their doctor on proven treatments like weight loss, dietary changes, and managing related health conditions.
Why do researchers test drugs in mice before humans?
Mouse studies help determine if a drug works and is safe before testing in humans. Mice have similar biological systems to humans but allow researchers to control variables carefully and test at doses that would be unsafe in people.
Want to Apply This Research?
- Users with fatty liver disease could track liver health markers through regular blood tests (ALT and AST levels) every 3 months, recording results in the app to monitor trends over time and share with their healthcare provider.
- Users could set daily reminders to log dietary choices (especially intake of methionine and choline-rich foods), exercise minutes, and weight to support liver health while waiting for new treatments to become available.
- Create a liver health dashboard tracking key metrics: liver enzyme levels from blood tests, weight, exercise frequency, and dietary adherence. Set quarterly check-in reminders to review trends and discuss results with a healthcare provider.
This article describes early-stage research conducted in laboratory mice. The findings have not been tested in humans and should not be interpreted as medical advice or a recommendation for treatment. KR-36996 is an experimental drug not approved for human use. People with fatty liver disease should consult with their healthcare provider about proven treatment options, which typically include weight loss, dietary modifications, and management of related conditions. This research is presented for educational purposes only and does not replace professional medical guidance.
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.